Proposed Directors of Tirupati Graphite explain why they have requisitioned an GM. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,176.00
Bid: 12,176.00
Ask: 12,178.00
Change: -14.00 (-0.11%)
Spread: 2.00 (0.016%)
Open: 12,304.00
High: 12,356.00
Low: 12,088.00
Prev. Close: 12,190.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Europe's STOXX 600 ends lower as rate uncertainty prevails

Tue, 21st May 2024 17:20

Focus on Fed minutes, Nvidia earnings

*

AstraZeneca rises on upbeat revenue forecast

*

Saipem climbs on winning $3.7 bln contract

*

STOXX 600 off 0.2%

May 21 (Reuters) - European stocks closed slightly lower on Tuesday, their third out of four sessions in the red, as caution around interest rate reductions dominated, with investors waiting for economic data due later in the week.

The pan-European STOXX 600 index ended 0.2% lower, after hitting a one-week low earlier in the session, with banks and luxury stocks leading sectoral losses, down around 0.9% each.

The lender-heavy Italian share index lagged regional peers, dropping 0.6% to hit a more than one-week low.

The STOXX index has eased from record highs since European Central Bank policymakers cautioned against expecting successive interest rate reductions in

June and July

.

Traders anticipate cuts worth 66 basis points from the ECB by year-end, according to the LSEG rate probabilities app, with the first seen in June.

Eurozone negotiated wage data for the first quarter along with May manufacturing data expected on Thursday could shed light on the state of the economy and offer clues to the trajectory of interest rates.

"Eurozone productivity is weak, so the bulk of the increase in labour costs over Q1 most likely reflects higher employee compensation. Elevated eurozone wage pressures suggest the easing cycle will be shallow," said Win Thin, global head of markets strategy at Brown Brothers Harriman.

Investors will also focus on minutes from the Fed's last policy meeting and chip giant Nvidia's earnings on Wednesday to see if the recent momentum that pushed U.S. and European equities to record highs continues.

On Tuesday, data showed German producer prices fell more than expected in April, mainly due to lower energy prices.

Drugmaker AstraZeneca rose 2.2%, among top gainers on the UK's main FTSE 100 index, after saying it aimed to increase revenue by about 75% to $80 billion by 2030.

The broader healthcare sector outperformed the main STOXX index with a 0.7% climb.

Italy's top insurer, Generali, dipped 1.5% after reporting first-quarter results, with some analysts pointing to lower-than-expected profitability in the property and casualty business.

The energy contractor

Saipem rose 4% after securing $3.7 billion in contracts with a subsidiary of French oil major TotalEnergies .

Swiss fastening systems maker SFS Group climbed 8%, after UBS upgraded the stock to "Buy" from "Neutral". (Reporting by Sruthi Shankar and Johann M Cherian in Bengaluru; Editing by Rashmi Aich and Kevin Liffey)

More News
Today 08:59

AstraZeneca cancer treatment Tagrisso recommended for approval in EU

(Alliance News) - AstraZeneca PLC said that, following further positive findings in clinical trial, Tagrisso has been recommended for use in the European Union.

Read more
Today 07:28

AstraZeneca's lung cancer treatment recommended for approval in EU

(Sharecast News) - AstraZeneca has announced that its Tagrisso treatment for advanced lung cancer, when combined with chemotherapy, has been recommended for approval by European regulators.

Read more
2 Jun 2024 20:03

Astra's Enhertu breast cancer trial shows 'unprecedented' results

June 2 (Reuters) - AstraZeneca and Daiichi Sankyo's Enhertu slows the progression of breast cancer by about five months in women whose disease worsened after endocrine therapy - even if they had very low levels of the mutant protein targeted by the drug, according to trial results announced on Sunday.

Read more
2 Jun 2024 15:58

Astra's Enhertu delays breast cancer in patients with low HER2 levels

June 2 (Reuters) - AstraZeneca and Daiichi Sankyo's Enhertu was shown in a large trial to delay the growth of hormone-sensitive breast cancer by about five months for people with low levels of HER2 protein whose cancer progressed following endocrine therapy, according to research presented on Sunday.

Read more
30 May 2024 09:23

LONDON BROKER RATINGS: Jefferies and UBS cut Anglo American

(Alliance News) - The following London-listed shares received analyst recommendations Thursday morning and on Wednesday:

Read more
30 May 2024 07:40

LONDON BRIEFING: Dr Martens cuts payout as profit plummets

(Alliance News) - Stocks in London are called to open lower on Thursday, with investors nervous ahead of Friday's US inflation print.

Read more
29 May 2024 08:54

IN BRIEF: AstraZeneca drug lowers cholesterol in phase 1 trial

AstraZeneca PLC - Cambridge, England-based pharmaceuticals - Reports positive results in a phase 1 trial of cholesterol drug candidate AZD0780, an oral small molecule PCSK9 inhibitor. Administered on top of rosuvastatin treatment, AZD0780 showed a statistically significant reduction in low-density lipoprotein cholesterol in plasma for test participants with hypercholesterolaemia, Astra says, while no serious adverse events were reported. "Elevated LDL-C levels in plasma is a key risk factor for cardiovascular disease and is estimated to cause 2.6 million deaths worldwide annually," Astra notes.

Read more
28 May 2024 07:02

AstraZeneca experimental lung cancer drug shows promising results

(Sharecast News) - AstraZeneca's experimental lung cancer drug showed improved overall survival rates in phase III trials, the pharmaceutical giant said on Tuesday.

Read more
27 May 2024 07:49

IN BRIEF: Astra, Daiichi hail positive survival data for Dato-DXd

AstraZeneca PLC - Cambridge, UK-based pharmaceutical firm - Alongside Japan's Daiichi Sankyo Co Ltd, notes positive data for datopotamab deruxtecan in phase III trial on lung cancer. Says the treatment, also known as Dato-DXd, showed a clinically meaningfully improvement in overall survival versus chemotherapy in advanced nonsquamous non-small cell lung cancer. The results build upon the positive progression-free survival findings presented back in 2023, Astra adds.

Read more
22 May 2024 09:53

LONDON BROKER RATINGS: Barclays cuts NextEnergy but lifts JLEN

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and on Tuesday:

Read more
22 May 2024 02:00

British firms expecting hard time in China market, lobby group warns

BEIJING, May 22 (Reuters) - British firms expect doing business in China to become harder over the next five years, a British business lobby group said on Wednesday, as Beijing strives to halt a retreat in foreign funds from a market once seen as the engine of global growth.

Read more
21 May 2024 19:00

Sector movers: Stocks slip amid light profit-taking

(Sharecast News) - Stocks ended a tad lower as investors waited on a raft of US central bank speakers scheduled for after the close of markets in London.

Read more
21 May 2024 17:04

LONDON MARKET CLOSE: London dips as eyes turn to UK inflation reading

(Alliance News) - Stock prices in London closed in the red on Tuesday, as investors nervously eye a key UK inflation reading, which could prompt the Bank of England to consider interest rate cuts.

Read more
21 May 2024 15:00

London close: Stocks fall ahead of key inflation reading

(Sharecast News) - London stocks ended in negative territory on Tuesday, influenced by the latest UK economic outlook from the International Monetary Fund (IMF) and comments from US Federal Reserve officials.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.